Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GNLX 
Genelux Corporation Common Stock (GNLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: GNLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $18
1 Year Target Price $18
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.5% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 148.07M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 5 | Beta -0.35 | 52 Weeks Range 1.95 - 5.88 | Updated Date 09/16/2025 |
52 Weeks Range 1.95 - 5.88 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.85 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.14% | Return on Equity (TTM) -98.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 122939099 | Price to Sales(TTM) 12362.41 |
Enterprise Value 122939099 | Price to Sales(TTM) 12362.41 | ||
Enterprise Value to Revenue 6302.51 | Enterprise Value to EBITDA -327.19 | Shares Outstanding 37773400 | Shares Floating 33391393 |
Shares Outstanding 37773400 | Shares Floating 33391393 | ||
Percent Insiders 13.24 | Percent Institutions 19.65 |
Upturn AI SWOT
Genelux Corporation Common Stock
Company Overview
History and Background
Genelux Corporation Common Stock was founded in 2005, initially focusing on early-stage cancer diagnostics. It pivoted to oncolytic virotherapy in 2010. A major milestone was the FDA Orphan Drug Designation for its lead candidate, Olvi-Vec. Recent evolution involves strategic partnerships for clinical trials.
Core Business Areas
- Oncolytic Virotherapy: Develops and commercializes oncolytic viruses for cancer treatment. Focus is on intravenous delivery and tumor-selective replication.
- Research and Development: Conducts preclinical and clinical research to advance its pipeline of oncolytic virus candidates.
Leadership and Structure
The company is led by a CEO with a background in biotechnology and oncology. The organizational structure consists of R&D, clinical development, and commercial operations departments, all reporting to the CEO.
Top Products and Market Share
Key Offerings
- Olvi-Vec: Genelux's lead oncolytic virus candidate currently in clinical trials for platinum-resistant/refractory ovarian cancer. Market share is currently 0% pending FDA approval, but projects to reach 30-40% within this patient population based on Phase 2 results, IF APPROVED. Competitors include Replimune Group Inc.(REPL).
Market Dynamics
Industry Overview
The oncolytic virotherapy market is experiencing rapid growth driven by increasing cancer incidence and advancements in biotechnology. Targeted therapies and personalized medicine are key trends.
Positioning
Genelux is a niche player in the oncolytic virotherapy market, focusing on intravenously delivered oncolytic viruses, which aims to target a broader set of tumors systemically. Their competitive advantage lies in the selectivity of Olvi-Vec for cancer cells and the potential for combination therapies.
Total Addressable Market (TAM)
The total addressable market (TAM) for oncolytic virotherapy is estimated at $1 billion by 2030. If approved, Genelux Corporation Common Stock positioned by addressing platinum-resistant/refractory ovarian cancer.
Upturn SWOT Analysis
Strengths
- Novel intravenous delivery technology
- Tumor-selective replication
- FDA Orphan Drug Designation
- Strong preclinical data
Weaknesses
- Limited financial resources
- Dependence on single lead candidate
- Lack of commercialized product
- Regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Positive clinical trial results
- Increasing market adoption of oncolytic virotherapy
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory delays
- Funding challenges
Competitors and Market Share
Key Competitors
- REPL
Competitive Landscape
Genelux faces strong competition from established pharmaceutical companies with greater financial resources and existing market presence. However, its novel intravenously delivered oncolytic virus technology offers a unique competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Genelux has not generated revenue over the past years.
Future Projections: Analyst estimates project significant revenue growth upon potential FDA approval of Olvi-Vec.
Recent Initiatives: Recent initiatives include expansion of clinical trials to other cancer indications and partnering.
Summary
Genelux is a development-stage biotechnology company with a promising oncolytic virus technology. While it has the potential to disrupt the cancer treatment market, its limited financial resources and dependence on a single lead candidate pose significant risks. Positive clinical trial results and strategic partnerships are critical for future success. The company needs to secure additional funding and navigate regulatory hurdles effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website, SEC filings, Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genelux Corporation Common Stock
Exchange NASDAQ | Headquaters Westlake Village, CA, United States | ||
IPO Launch date 2023-01-26 | Chairman, CEO & President Mr. Thomas D. Zindrick J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 24 | Website https://www.genelux.com |
Full time employees 24 | Website https://www.genelux.com | ||
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.